Treatment with remdesivir was associated with a shorter time to recovery in patients hospitalized with coronavirus disease 2019 (COVID-19), according to peer-reviewed data published in the New England Journal of Medicine.
The FDA has granted Fast Track designation to the vaccine candidate, mRNA-1273 (Moderna), against the novel coronavirus (SARS-CoV-2).
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.
The dramatic and rapid expansion in telemedicine has left many clinicians scrambling to institute this new means of conducting medicine; and even more seasoned providers who had been using telemedicine in their practice must learn to move telemedicine from the periphery to front and center of their practice.
The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity.
Data that informed these label changes came from research funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Convalescent plasma, which is collected from patients who have recovered from COVID-19, contains antibodies to SARS-CoV-2, the virus that causes the disease.
To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.
